Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. (trading symbol: OBLN) on January 22, 2021, reporting events occurring on January 18, 2021. The company is an emerging growth company incorporated in Delaware. The filing addresses executive compensation adjustments in the context of a pending merger with ReShape Lifesciences Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and merger-related contingencies.
Material Changes
- Executive Salary Increases: The Board approved an increase in the annual base salary for CEO Andrew Rasdal and CFO Nooshin Hussainy to $400,000 each.
- Effective Period: The salary increase is effective from January 1, 2021, through the earlier of the closing of the Merger or April 30, 2021.
- Retention Agreement Amendment: The change of control transaction bonus of $250,000 for both executives is now payable upon the earlier of the Merger closing or April 30, 2021.
Guidance, Outlook, and Risks
The filing references an Agreement and Plan of Merger dated January 19, 2021, between Obalon Therapeutics, ReShape Lifesciences Inc., and Optimus Merger Sub, Inc. The compensation changes are contingent upon the closing of this transaction. No specific financial guidance or risk factors beyond the merger contingency are detailed in this report.
Investor Verification Checklist
- Verify the status and expected closing date of the merger with ReShape Lifesciences Inc.
- Confirm the total cash outlay for the $250,000 change of control bonuses for the CEO and CFO.
- Review the full Merger Agreement for details on the transaction structure and shareholder approval requirements.
- Check subsequent filings for updates on the April 30, 2021 deadline for the compensation adjustments.